Leerink Partners Initiates Coverage On Arcturus Therapeutics with Outperform Rating, Announces Price Target of $70
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has initiated coverage on Arcturus Therapeutics (NASDAQ:ARCT) with an Outperform rating and a price target of $70.
August 12, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has initiated coverage on Arcturus Therapeutics with an Outperform rating and a price target of $70.
The initiation of coverage with an Outperform rating and a price target of $70 by Leerink Partners is likely to positively impact the stock price of Arcturus Therapeutics in the short term. Such ratings often lead to increased investor interest and buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100